Fang Yu1, Jie-Yuan Jin2, Ji-Qiang He1, Liang-Liang Fan2, Zi-Jun Jiao2, Pan-Feng Wu1, Ju-Yu Tang1, Rong Xiang1,2,3. 1. Department of Orthopaedics, Xiangya Hospital of Central South University Changsha, China. 2. School of Life Sciences, Central South University Changsha, China. 3. Human Key Laboratory of Animal Models for Human Diseases, School of Life Sciences, Central South University Changsha, China.
Abstract
OBJECTIVE: Mucolipidosis II and III alpha/beta (ML II & ML III alpha/beta) are rare autosomal recessive lysosomal storage disorders. ML II is clinically evident from birth with a progressive course and fatal outcome in childhood. The typical phenotypes of ML II include limited statural growth, craniofacial abnormality, skeletal malformation, intelligence developmental deficiency and visceral organ abnormality. ML III is milder than ML II. Mutations in GNPTAB cause the ML II/III. METHODS: Two families with ML II/III (initially undiagnosed) were recruited. We applied whole-exome sequencing (WES) and filtered mutations by genes causing lysosomal storage diseases with skeletal involvement. Mutational analysis and co-segregation confirmation were then performed. RESULTS: We presented two families with ML II or ML III alpha/beta. By WES, the compound heterozygosity of GNPTAB (c.2404C>T, p.Q802* and c.2590dup, p.E864Gfs*4) is identified in a family with ML II, and c.1364C>T, p.A455V and c.2715+1G>A are detected in a family with ML III alpha/beta. CONCLUSION: We detected the causative mutations in two ML II/III families by WES and confirmed their diagnosis of the diseases. The present identification of mutations expands the spectrum of known GNPTAB mutations and it may contribute to novel approaches to genetic diagnosis and counseling for patients with ML II/III. IJCEP
OBJECTIVE:Mucolipidosis II and III alpha/beta (ML II & ML III alpha/beta) are rare autosomal recessive lysosomal storage disorders. ML II is clinically evident from birth with a progressive course and fatal outcome in childhood. The typical phenotypes of ML II include limited statural growth, craniofacial abnormality, skeletal malformation, intelligence developmental deficiency and visceral organ abnormality. ML III is milder than ML II. Mutations in GNPTAB cause the ML II/III. METHODS: Two families with ML II/III (initially undiagnosed) were recruited. We applied whole-exome sequencing (WES) and filtered mutations by genes causing lysosomal storage diseases with skeletal involvement. Mutational analysis and co-segregation confirmation were then performed. RESULTS: We presented two families with ML II or ML III alpha/beta. By WES, the compound heterozygosity of GNPTAB (c.2404C>T, p.Q802* and c.2590dup, p.E864Gfs*4) is identified in a family with ML II, and c.1364C>T, p.A455V and c.2715+1G>A are detected in a family with ML III alpha/beta. CONCLUSION: We detected the causative mutations in two ML II/III families by WES and confirmed their diagnosis of the diseases. The present identification of mutations expands the spectrum of known GNPTAB mutations and it may contribute to novel approaches to genetic diagnosis and counseling for patients with ML II/III. IJCEP
Authors: Stephan Tiede; Stephan Storch; Torben Lübke; Bernard Henrissat; Ruth Bargal; Annick Raas-Rothschild; Thomas Braulke Journal: Nat Med Date: 2005-10-02 Impact factor: 53.440
Authors: Renata Voltolini Velho; Raffaella De Pace; Sarah Klünder; Fernanda Sperb-Ludwig; Charles Marques Lourenço; Ida V D Schwartz; Thomas Braulke; Sandra Pohl Journal: Hum Mol Genet Date: 2015-03-18 Impact factor: 6.150
Authors: Hosneara Akter; Mohammad Shahnoor Hossain; Nushrat Jahan Dity; Md Atikur Rahaman; K M Furkan Uddin; Nasna Nassir; Ghausia Begum; Reem Abdel Hameid; Muhammad Sougatul Islam; Tahrima Arman Tusty; Mohammad Basiruzzaman; Shaoli Sarkar; Mazharul Islam; Sharmin Jahan; Elaine T Lim; Marc Woodbury-Smith; Dimitri James Stavropoulos; Darren D O'Rielly; Bakhrom K Berdeiv; A H M Nurun Nabi; Mohammed Nazmul Ahsan; Stephen W Scherer; Mohammed Uddin Journal: NPJ Genom Med Date: 2021-02-16 Impact factor: 8.617